Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

Completed · Phase 3

Conditions studied: Bunionectomy, Hallux Valgus

In brief

The study is conducted sequentially in two parts. Part A: The purpose is to obtain information on pharmacokinetic (PK) profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL. Part B: The purpose is to evaluate the efficacy and safety of the preferred dosage of EXPAREL from Part A compared with bupivacaine HCl.

Key facts

Study ID
NCT05157841
Run by
Pacira Pharmaceuticals, Inc
People needed
185
Starts
2022-02-15
Expected to finish
2022-08-17
Last updated by the study team
2025-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.